Alerta

Pharmaceutical composition for treating Alzheimer disease

Resumen de: CN120361187A

The invention belongs to the field of medicine application, and particularly relates to a medicine composition for treating Alzheimer disease. The RIAFP and the AFGP8 have a remarkable improvement effect on cognitive impairment in an AD model, and the proteins can be used as novel biological therapeutic agents and provide a potential treatment strategy for neurodegenerative diseases such as AD and the like.

Levodopa fatty acid derivatives, formulations thereof, and their uses for the treatment of parkinson’s disease

Resumen de: NZ812405A

A levodopa derivative including a compound or pharmaceutically acceptable salt, hydrate, and/or solvate thereof, wherein the compound includes substituents which, in aggregate, contain at least 6 carbon atoms which are only bonded to either other carbon atoms or to hydrogen atoms. The levodopa derivative may be formulated as a composition including one or more pharmaceutically acceptable carriers or excipients. The levodopa derivative may be part of a pharmaceutical composition including micro or nano particles in which the levodopa derivative is encapsulated in the pharmaceutically acceptable polymer. The levodopa derivative can be used to treat Parkinson’s disease by administering to a mammal an amount sufficient to treat Parkinson’s disease.

Application of Piezo1 agonist and pharmaceutical preparation for nose

Resumen de: CN120361007A

The invention discloses an application of a Piezo1 agonist and a pharmaceutical preparation used for a nose, including an application of the Piezo1 agonist in preparation of a drug for promoting removal of cerebrospinal fluid and/or intracerebral metabolic waste through nasal tissues, and an application of the Piezo1 agonist in preparation of a drug for improving a nasal lymphatic vessel drainage function. The invention also provides a nasal drug delivery preparation containing the Yoda1. According to the invention, the Piezo1 agonist is proposed for the first time to eliminate A beta by improving the drainage function of nasal lymphatic vessels so as to improve cognitive and olfactory dysfunctions of the Alzheimer's disease, a nasal administration strategy is provided, and a new drug intervention direction is provided for AD treatment. The Yoda1 activates a signal channel of nasal lymphatic vessel Piezo1, not only can enhance the removal of A beta, but also can act on a meningelymphatic system through a nasal cavity-brain channel to further improve the metabolic balance of A beta in the brain, so that the Yoda1 has a relatively good clinical application prospect.

Bifidobacterium adolescentis for improving urticaria and Alzheimer as well as product and application thereof

Resumen de: CN120366145A

The invention provides bifidobacterium adolescentis for improving urticaria and Alzheimer as well as a product and application thereof. The bifidobacterium adolescentis NHNK-622 disclosed by the invention is preserved in the China Center for Type Culture Collection on December 05, 2024, and the preservation number of the bifidobacterium adolescentis NHNK-622 is CCTCC (China Center for Type Culture Collection) NO: M 20242734. The NHNK-622 has the effects of inhibiting the growth of klebsiella pneumonia and/or generating alcohol, agglutinating klebsiella pneumonia, tolerating 10% alcohol, reducing alcohol-induced damaged skin cutin barrier and inflammation, reducing alcohol-induced damaged brain microvascular barrier and inflammation, improving the klebsiella pneumonia-induced damaged survival rate of brain microvascular endothelial cells, and improving the activity of the brain microvascular endothelial cells. Klebsiella pneumonia induced damage to brain microvascular barriers and inflammation is reduced, and Klebsiella pneumonia induced damage to intestinal barriers and inflammation is reduced.

Lactobacillus johnsonii A21065 capable of resisting oxidation, prolonging life and delaying Parkinson's symptom as well as product and application of lactobacillus johnsonii A21065

Resumen de: CN120366142A

The invention discloses lactobacillus johnsonii A21065 capable of resisting oxidation, prolonging life and delaying Parkinson's disease as well as a product and application of the lactobacillus johnsonii A21065, and belongs to the technical field of functional strains. The preservation number of the lactobacillus johnsonii A21065 is GDMCC (China General Microbiological Culture Collection Center) No: 65767. In a caenorhabditis elegans model, the lactobacillus johnsonii A21065 shows that the lactobacillus johnsonii A21065 has better effects of improving the oxidation resistance of nematodes, resisting environmental stress and prolonging the life, also shows a good effect in in-vitro experiments of resisting artificial gastrointestinal fluid, resisting cholate and the like, meanwhile, the lactobacillus johnsonii A21065 also has an effect of improving the cognition of a Parkinson nematode model, and the lactobacillus johnsonii A21065 has a good application prospect. The invention has important significance for preventing and/or treating Parkinson's disease.

Application of anti-aging drug in treatment of Alzheimer's disease

Resumen de: CN120361215A

The invention relates to application of an anti-aging drug to treatment of Alzheimer's disease, and particularly discovers that some drugs not only can reverse aging of myeloid cells playing an important role in innate immunity, but also can improve aging of organ level, and can obviously improve aging of brain and liver, lung, skin and kidney organs except the brain; in addition to cell and protein levels, the drugs can also effectively reverse senescence transcriptome, and new evidence is provided for systematic drug screening. Moreover, the medicines can recover important structures of cerebral cortex and hippocampus which are related to cognitive memory, which shows that the medicines have great potential of improving cognitive ability related to senescence. Besides, the medicines can effectively improve cognitive impairment of 5 * FAD model mice, relieve brain A beta precipitation and effectively reverse transcriptome characteristics of Alzheimer's disease states, which indicates that the medicines have the potential of resisting aging and treating aging-related diseases, especially Alzheimer's disease.

Application of exosome derived from olfactory mucosa mesenchymal stem cells pretreated based on active peptide in improvement of neuroinflammation

Resumen de: CN120366205A

The invention relates to application of an exosome derived from olfactory mucosa mesenchymal stem cells pretreated based on active peptide in improvement of neuroinflammation, in particular to a treatment strategy for neuroinflammation of Alzheimer's disease (AD). An IFN-FGF fusion protein (SEQ ID NO: 3) and a coding gene (SEQ ID NO: 4) of the IFN-FGF fusion protein are constructed, and the IFN-FGF fusion protein and the coding gene (SEQ ID NO: 4) are used for in-vitro pretreatment of OM-MSCs, so that the A-MS Cs-Exo exosome with anti-inflammatory and neuroprotective functions is obtained. In an A beta oligomer-induced AD neuroinflammation model, the A-MSCs-Exo significantly alleviates neuroinflammation and cognitive impairment by inhibiting excessive activation of hippocampal Iba1 + microglia cells, reducing serum IL-6 level, improving SOD activity and improving Morris water maze behavioral performance, the effect is better than that of traditional FGF-1 pretreatment (B-MSCs-Exo) and untreated exosome (C-MSCs-Exo), and the A-MSCs-Exo can be used for preparing the A beta oligomer-induced AD neuroinflammation model. The invention provides a novel exosome intervention strategy for AD treatment.

(Aza) Spiroheptane Derivatives For The Treatment Of Neurodegenerative Disorders

Resumen de: CN120379996A

The present application relates to compounds of formula (B1A), (B1B), (B1C) or salts, solvates, hydrates, polymorphs, tautomers, racemes or stereoisomers thereof, pharmaceutical compositions comprising such compounds, and these compounds for use as pharmaceuticals, in particular for use in the treatment of neurodegenerative disorders such as Alzheimer's disease. # imgabs0 #

HETEROCYCLIC PLA2G15 INHIBITORS AND THEIR USE IN THERAPY, IN THE TREATMENT OF DISEASES CHARACTERIZED BY LYSOSOMAL DYSREGULATION

Resumen de: WO2025153715A1

The current invention relates to PLA2G15 inhibitors represented by formula (I), and corresponding compositions and uses. Preferably, the inhibitors and compositions are for use in the treatment of lysosomal storage diseases, Alzheimer's disease and Parkinson's disease; in particular for use in the treatment of Niemann Pick type C or a neuronal ceroid lipofuscinosis such as CLN3 disease or Batten disease, CLN5 disease, or GRN frontotemporal dementia.

PLA2G15 INHIBITORS

Resumen de: WO2025153720A1

The current invention relates to PLA2G15 inhibitors represented by formula (I), and corresponding compositions and uses. Preferably, the inhibitors and compositions are for use in the treatment of lysosomal storage diseases, Alzheimer's disease and Parkinson's disease; in particular for use in the treatment of Niemann Pick type C or a neuronal ceroid lipofuscinosis such as CLN3 disease or Batten disease, CLN5 disease, or GRN frontotemporal dementia.

ANTI-INFLAMMATORY COMPOSITION AND USE

Resumen de: WO2025153832A1

8Z, 11Z, 14Z, 17Z-eicosatetraenoic acid (ETA) and/or 10Z, 13Z, 16Z-docosa-10,l 3, 16-trienoic acid (DTA) have been shown to have anti-neuroinflammatory properties and suitable for use in the treatment of neurodegenerative disease, such as Alzheimer's disease. The anti-neuroinflammatory effect of using ETA and/or DTA can be surprisingly, and optionally synergistically increased by using ETA and/or DTA in combination with eicosapentaenoic acid (EPA),docosahexaenoic acid (DHA), stearidonic acid (6, 9, 12, 15 -octadecatrienioc acid) (SDA), gamma linolenic acid (6, 9, 12-octadecatrienioc acid) (GLA), dihomo γ linolenic acid (8, 11, 14-eicosatraenoic acid) (DGLA), and/or 7, 10, 13, 16, 19-docosapentaenoic acid (DPA), preferably docosahexaenoic acid (DHA).

COMPOSITIONS AND METHODS RELATED TO THE METHYLATION OF HISTONE H1.0 PROTEIN

Resumen de: US2025237652A1

Provided herein are compositions and methods related to the production and detection of a histone H1.0 protein dimethylated at lysine residue 180 (K180) (H1.0K180me2 protein) or a histone H1.0 peptide dimethylated at a lysine residue corresponding to K180 (H1.0K180me2 peptides). The H1.0K180me2 protein and H1.0K180me2 peptides are useful for applications including, but not limited to, molecular diagnostics of DNA damage, genotoxic stress, radiation exposure, and Alzheimer's disease, therapeutics, monitoring of therapeutic regimens, patient stratification, and drug screening. Also provided herein are antibodies specific for the H1.0K180me2 protein and H1.0K180me2 peptides.

LIPOSOMAL COMPOSITION FOR USE IN A METHOD OF TREATING PARKINSON' S DISEASE

Resumen de: AU2024208984A1

The present invention relates to a liposomal composition for use in a method of treating Parkinson's disease. The liposomal composition comprises sphingomyelin in a lipid bilayer and a therapeutically ef fective amount of monosialotetrahexosylganglioside (GM1), wherein a therapeutically ef fective dose of said liposomal composition is administered at most every 4 days in a primary mode of administration with at least 3 days between each administration; preferably at most every 6 days in a primary mode of administration with at least 5 days between each administration; most preferably at most every 7 days in a primary mode of administration with at least 6 days between each administration.

PLA2G15 INHIBITORS

Resumen de: WO2025153719A1

The current invention relates to PLA2G15 inhibitors represented by formula (I), and corresponding compositions and uses. Preferably, the inhibitors and compositions are for use in the treatment of lysosomal storage diseases, Alzheimer's disease and Parkinson's disease; in particular for use in the treatment of Niemann Pick type C or a neuronal ceroid lipofuscinosis such as CLN3 disease or Batten disease, CLN5 disease, or GRN frontotemporal dementia.

ANTI-RETROVIRAL THERAPIES AND REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE

Resumen de: US2025235464A1

Described herein are methods for inhibiting generation of one or more non-classical variant(s) of amyloid precursor protein (APP) gene. Provided herein are methods for diagnosing an individual having or suspected of having Alzheimer's disease following identification of an expression profile or an activity profile of the one or more non-classical variant(s) and treating the individual using a reverse transcriptase inhibitor or salt thereof.

PLA2G15 INHIBITORS

Resumen de: WO2025153718A1

The current invention relates to PLA2G15 inhibitors represented by formula (I), and corresponding compositions and uses. Preferably, the inhibitors and compositions are for use in the treatment of lysosomal storage diseases, HIV, Alzheimer's disease and Parkinson's disease; in particular for use in the treatment of Niemann Pick type C or a neuronal ceroid lipofuscinosis such as CLN3 disease or Batten disease, CLN5 disease, or GRN frontotemporal dementia.

PLA2G15 INHIBITORS

Resumen de: WO2025153721A1

The current invention relates to PLA2G15 inhibitors represented by formula (VI), and corresponding compositions and uses. Preferably, the inhibitors and compositions are for use in the treatment of lysosomal storage diseases, HIV, Alzheimer's disease and Parkinson's disease; in particular for use in the treatment of Niemann Pick type C or a neuronal ceroid lipofuscinosis such as CLN3 disease or Batten disease, CLN5 disease, or GRN frontotemporal dementia.

COMPOSITIONS OF ANTIOXIDANT TRANSLATION MODULATORS FOR TREATING NEURODEGENERATIVE DISORDERS

Resumen de: WO2025155903A1

The present invention provides compositions and methods for treating disorders of the central nervous system. In some embodiments, compositions of the present invention comprise novel compounds further comprising a heterocyclic core optionally fused with a 6-membered carbocyclic ring and a non-electrophilic substituent. In one embodiment, the disorder of the central nervous system which can be treated using the present invention is Alzheimer's disease.

COMPOSITION FOR PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE

Resumen de: WO2025154692A1

Provided is a novel means capable of efficiently inhibiting beta-secretase (BACE1). Specifically, a BACE1-inhibiting composition containing a specific glycerophospholipid is provided.

METHOD OF PROLONGING THE SURVIVAL OF A SUBJECT WITH ALS

Resumen de: WO2025154076A1

This invention provides a method of prolonging the survival of subjects afflicted with ALS by administering a composition comprising pridopidine or pharmaceutically acceptable salt thereof.

METHOD FOR TREATING ALZHEIMER'S DISEASE

Resumen de: WO2025152934A1

Provided herein is a method for treating Alzheimer's disease. The method comprises orally administering to a subject in need thereof 50-100 mg/day of orelabrutinib. The method reduces neuroinflammation and improves the cognitive functions such as learning and memory processes of the subject.

DRUG COMBINATION FOR TREATING ALZHEIMER'S DISEASE AND PHARMACEUTICAL COMPOSITION THEREOF

Resumen de: WO2025152110A1

A drug combination for treating Alzheimer's disease and a pharmaceutical composition thereof. The pharmaceutical composition comprises: (a) a prophylactically or therapeutically effective amount of HDAC6 inhibitor; and (b) a prophylactically or therapeutically effective amount of GSK-3β inhibitor. The components of the drug combination are used in combination, so that the therapeutic effect of each single drug on Alzheimer's disease can be synergistically enhanced. Moreover, significant weight loss or abnormal behavior does not appear in mice after drug administration, showing that the drug combination has good efficacy and safety.

VALACYCLOVIR AND CELECOXIB FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND COVID-19

Resumen de: AU2023341167A1

The present disclosure relates to methods of treating Alzheimer's disease, diseases and/or conditions associated with Covid-19 infection, including long COVID, a post-acute infection syndrome, or symptoms of orthostatic intolerance comprising administration of a therapeutically-effective combination of a COX-2 inhibitor and an antiviral compound.

Small nucleic acid targeting PIKfyve gene as well as pharmaceutical composition and application thereof

Resumen de: CN120350010A

The invention discloses a small nucleic acid targeting a PIKfyve gene as well as a preparation method, a pharmaceutical composition and application of the small nucleic acid. According to the small nucleic acid targeting the PIKfyve gene disclosed by the invention, the expression level of PIKfyve mRNA (messenger Ribonucleic Acid) is obviously reduced at the cellular level, and the axon length of neuronal cells is obviously increased; in-vivo verification shows that the body function and the survival condition of mice with amyotrophic lateral sclerosis can be remarkably improved. The small nucleic acid targeting the PIKfyve gene disclosed by the invention provides a new thought for treating neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson's disease and Alzheimer's disease.

Composition for preventing or treating Parkinson's disease

Nº publicación: KR20250111720A 22/07/2025

Solicitante:

강원대학교산학협력단